Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
To assess the pharmacokinetics (PK) and evaluate the safety of intravenous (IV) infusion of TR-701 free acid (FA) in subjects with advanced renal impairment compared with matched control subjects with normal renal function
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BMI between 18.0 and 40.0 kg/m2 inclusive
Male or female subjects between 18 and 75 years of age
Stable dosage of medication for 30 days
for dialysis patients, receiving chronic and stable maintenance hemodialysis for at least 3 months
You may not be if
Functioning transplanted solid organ
High tyramine diet
Significant, unstable, or life-threatening condition or organ or system condition or disease, other than kidney disease in renal subjects
